Lifecore Biomedical Inc. (LFCR)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Lifecore Biomedical Inc..
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 4 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 4.40 $ — 14% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
NeutralGeprüft am 13.07.2026 gegen den Übergangs-Geschäftsbericht (10-KT) für die Rumpfperiode 26.05.–31.12.2025 (eingereicht 16.03.2026), den Geschäftsbericht (10-K) zum 25.05.2025 (eingereicht 07.08.2025) und die vier jüngsten Quartalsberichte (10-Q): In den ausgewerteten SEC-Filings von Lifecore Biomedical findet sich kein einziger Treffer zu „artificial intelligence“, „machine learning“, „generative“, „LLM“ oder „AI“ — weder als Umsatzquelle noch als operativer Einsatz noch als konkretes Geschäftsrisiko. Lifecore ist ein Auftragsfertiger (CDMO) für sterile Injektionspräparate und Hersteller pharmazeutischer Hyaluronsäure; die Berichte behandeln Fermentation, Reinraum-Abfüllung, cGMP-Regulierung, Kundenkonzentration und Kapitalstruktur, aber keinerlei KI-Bezug. Negativ-Befund über sechs Filings dokumentiert — nach dem Kriterienkatalog eindeutig „neutral“.
View the full file — quotes, sources, reviewed filings
Filings Reviewed: 10-Q 2026-05-06 · 10-Q 2025-11-06 · 10-Q 2025-04-03 · 10-Q 2025-01-02 · 10-KT 2026-03-16 · 10-K 2025-08-07
Rated on July 13, 2026 · How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 55.2% above the current price.
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Next Reporting Date
- Expected Earnings per Share
- -0.17 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q3 | -0.43 | – | 25 | 0.70 | -65.70 | -1 | -4 |
| 2024: Q4 | -0.18 | -146.20 | 33 | 8.00 | -20.20 | -6 | -9 |
| 2025: Q1 | -0.39 | – | 35 | 37.70 | -42.00 | 1 | -4 |
| 2025: Q2 | -0.03 | – | 36 | -3.80 | -3.10 | 5 | 3 |
| 2025: Q3 | -0.27 | – | 31 | 25.90 | -32.10 | 2 | 0 |
| 2026: Q1 | -0.40 | – | 23 | -28.80 | -64.60 | 5 | 4 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Lifecore Biomedical, Inc. ist zusammen mit seinen Tochtergesellschaften eine integrierte Auftragsentwicklungs- und -fertigungsorganisation (CDMO), die Kunden in den USA, Belgien, den Niederlanden und international bedient.
| Employees | 382 |
|---|---|
| Headquarters | Chaska, MN |
| Website | lifecore.com |
| IPO Date | 15. Feb 1996 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Paul Josephs | President, CEO & Director | 1966 |
| Ryan D. Lake CPA | Executive VP & CFO | 1977 |
| Thomas D. Salus | Chief Legal & Administration Officer and Corporate Secretary | 1970 |
| Thomas Guldager | Senior Vice President of Operations | – |
| Aaron Perlitsh | Director of Internal Audit & Chief Compliance Officer | – |
| Jackie Q. Klecker | Executive Vice President of Quality & Development Services | – |
| Mark DaFonseca | Chief Commercial Officer | – |
| Parker K. Javid | Vice President | 1969 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.